SI3126354T1 - Halogenirani kinazolin-THF-amini kot PDE1 inhibitorji - Google Patents

Halogenirani kinazolin-THF-amini kot PDE1 inhibitorji

Info

Publication number
SI3126354T1
SI3126354T1 SI201531112T SI201531112T SI3126354T1 SI 3126354 T1 SI3126354 T1 SI 3126354T1 SI 201531112 T SI201531112 T SI 201531112T SI 201531112 T SI201531112 T SI 201531112T SI 3126354 T1 SI3126354 T1 SI 3126354T1
Authority
SI
Slovenia
Prior art keywords
thf
amines
pde1 inhibitors
quinazolin
halogenated
Prior art date
Application number
SI201531112T
Other languages
English (en)
Inventor
Jan Kehler
Lars Kyhn Rasmussen
Morten Langgard
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of SI3126354T1 publication Critical patent/SI3126354T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
SI201531112T 2014-04-04 2015-03-27 Halogenirani kinazolin-THF-amini kot PDE1 inhibitorji SI3126354T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201400194 2014-04-04
PCT/EP2015/056713 WO2015150254A1 (en) 2014-04-04 2015-03-27 Halogenated quinazolin-thf-amines as pde1 inhibitors
EP15713186.3A EP3126354B1 (en) 2014-04-04 2015-03-27 Halogenated quinazolin-thf-amines as pde1 inhibitors

Publications (1)

Publication Number Publication Date
SI3126354T1 true SI3126354T1 (sl) 2020-04-30

Family

ID=52779655

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201531112T SI3126354T1 (sl) 2014-04-04 2015-03-27 Halogenirani kinazolin-THF-amini kot PDE1 inhibitorji

Country Status (38)

Country Link
US (2) US10005764B2 (sl)
EP (1) EP3126354B1 (sl)
JP (1) JP6554116B2 (sl)
KR (1) KR20160138084A (sl)
CN (2) CN106132953B (sl)
AP (1) AP2016009521A0 (sl)
AR (1) AR101155A1 (sl)
AU (1) AU2015239696B2 (sl)
CA (1) CA2943011A1 (sl)
CL (1) CL2016002515A1 (sl)
CR (1) CR20160463A (sl)
CY (1) CY1122784T1 (sl)
DK (1) DK3126354T3 (sl)
DO (1) DOP2016000263A (sl)
EA (1) EA032579B1 (sl)
EC (1) ECSP16082599A (sl)
ES (1) ES2776359T3 (sl)
GE (1) GEP20186920B (sl)
GT (1) GT201600213A (sl)
HR (1) HRP20200369T1 (sl)
IL (1) IL248078B (sl)
JO (1) JO3628B1 (sl)
LT (1) LT3126354T (sl)
MA (1) MA39837B1 (sl)
MX (1) MX364519B (sl)
PE (1) PE20161380A1 (sl)
PH (1) PH12016501938A1 (sl)
PL (1) PL3126354T3 (sl)
PT (1) PT3126354T (sl)
RS (1) RS60017B1 (sl)
RU (1) RU2692808C2 (sl)
SG (1) SG11201608190YA (sl)
SI (1) SI3126354T1 (sl)
SV (1) SV2016005297A (sl)
TW (1) TWI664178B (sl)
UA (1) UA119166C2 (sl)
WO (1) WO2015150254A1 (sl)
ZA (1) ZA201606566B (sl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3126354T3 (da) 2014-04-04 2020-03-09 H Lundbeck As Halogenerede quinazolin-thf-aminer som pde1-inhibitorer
JP7111720B2 (ja) 2016-12-28 2022-08-02 ダート・ニューロサイエンス・エルエルシー Pde2阻害剤としての置換ピラゾロピリミジノン化合物
CA3120971A1 (en) * 2017-11-27 2019-05-31 Dart Neuroscience, Llc Substituted furanopyrimidine compounds as pde1 inhibitors
CN117105809B (zh) * 2023-10-20 2024-05-03 中国农业大学 一种苯甲酰苯胺化合物及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10042058A1 (de) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
GB0229281D0 (en) * 2002-12-16 2003-01-22 Novartis Ag Organic compounds
CN1784391B (zh) * 2003-03-03 2010-06-09 沃泰克斯药物股份有限公司 可用作离子通道调控剂的喹唑啉
GB0327319D0 (en) * 2003-11-24 2003-12-24 Pfizer Ltd Novel pharmaceuticals
US20060019975A1 (en) * 2004-07-23 2006-01-26 Pfizer Inc Novel piperidyl derivatives of quinazoline and isoquinoline
US20060183763A1 (en) * 2004-12-31 2006-08-17 Pfizer Inc Novel pyrrolidyl derivatives of heteroaromatic compounds
EP1996587A1 (en) * 2006-02-23 2008-12-03 Pfizer Products Incorporated Substituted quinazolines as pde10 inhibitors
US20070265258A1 (en) * 2006-03-06 2007-11-15 Ruiping Liu Quinazoline derivatives as phosphodiesterase 10 inhibitors
EP2480537A1 (en) * 2009-09-24 2012-08-01 Basf Se Aminoquinazoline compounds for combating invertebrate pests
US20130116241A1 (en) * 2011-11-09 2013-05-09 Abbvie Inc. Novel inhibitor compounds of phosphodiesterase type 10a
TW201609713A (zh) * 2013-12-19 2016-03-16 H 朗德貝克公司 作爲pde1抑制劑之喹唑啉-thf-胺
TW201611834A (en) 2014-02-07 2016-04-01 Lundbeck & Co As H Hexahydrofuropyrroles as PDE1 inhibitors
EA032559B1 (ru) 2014-04-04 2019-06-28 Пфайзер Инк. Бициклические аннелированные гетероарильные или арильные соединения и их применение в качестве ингибиторов irak4
DK3126354T3 (da) 2014-04-04 2020-03-09 H Lundbeck As Halogenerede quinazolin-thf-aminer som pde1-inhibitorer
AR099936A1 (es) 2014-04-04 2016-08-31 Sanofi Sa Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
AR099937A1 (es) 2014-04-04 2016-08-31 Sanofi Sa Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
CA2944256A1 (en) 2014-04-04 2015-10-08 F. Hoffmann-La Roche Ag 5,6-disubstituted pyridine-2-carboxamides as cannabinoid receptor agonists
MX2016012689A (es) 2014-04-04 2016-12-14 Hoffmann La Roche Piridin-2-amidas utiles como agonistas del receptor 2 cannabinoide (cb2).

Also Published As

Publication number Publication date
RS60017B1 (sr) 2020-04-30
TW201620901A (zh) 2016-06-16
EA032579B1 (ru) 2019-06-28
PE20161380A1 (es) 2017-01-15
AU2015239696A1 (en) 2016-10-06
CL2016002515A1 (es) 2016-12-16
TWI664178B (zh) 2019-07-01
DK3126354T3 (da) 2020-03-09
ECSP16082599A (es) 2017-02-24
WO2015150254A1 (en) 2015-10-08
CY1122784T1 (el) 2021-05-05
AP2016009521A0 (en) 2016-10-31
LT3126354T (lt) 2020-03-25
UA119166C2 (uk) 2019-05-10
CN106132953A (zh) 2016-11-16
RU2016138743A (ru) 2018-05-07
ZA201606566B (en) 2017-11-29
SG11201608190YA (en) 2016-10-28
CN106132953B (zh) 2019-03-22
AR101155A1 (es) 2016-11-30
JP6554116B2 (ja) 2019-07-31
EP3126354A1 (en) 2017-02-08
GEP20186920B (en) 2018-11-12
MX2016012955A (es) 2016-12-07
US20170022186A1 (en) 2017-01-26
CR20160463A (es) 2017-03-06
GT201600213A (es) 2019-07-29
IL248078B (en) 2018-11-29
SV2016005297A (es) 2016-11-30
CN109999039A (zh) 2019-07-12
US10526319B2 (en) 2020-01-07
RU2692808C2 (ru) 2019-06-27
RU2016138743A3 (sl) 2019-01-15
US10005764B2 (en) 2018-06-26
DOP2016000263A (es) 2016-11-30
PT3126354T (pt) 2020-03-17
KR20160138084A (ko) 2016-12-02
MA39837B1 (fr) 2020-05-29
US20190144434A1 (en) 2019-05-16
EA201691773A1 (ru) 2017-01-30
CA2943011A1 (en) 2015-10-08
PH12016501938A1 (en) 2017-02-06
EP3126354B1 (en) 2020-01-22
ES2776359T3 (es) 2020-07-30
JP2017509680A (ja) 2017-04-06
PL3126354T3 (pl) 2020-06-15
AU2015239696B2 (en) 2019-10-24
MX364519B (es) 2019-04-30
HRP20200369T1 (hr) 2020-08-07
JO3628B1 (ar) 2020-08-27

Similar Documents

Publication Publication Date Title
IL287113A (en) smyd inhibitors
IL251420A0 (en) Triazolopyrazinones as pde1 inhibitors
HK1249097A1 (zh) 作為pde1抑制劑的咪唑並三嗪酮
GB2531928B (en) Image-stitching for dimensioning
IL246785A0 (en) Benzimidazole-2-amines as midh1 inhibitors
GB201817189D0 (en) Image-stitching for dimensioning
HK1226398A1 (zh) 作為midh1抑制劑的苯並咪唑-2-胺
HK1252098A1 (zh) 作為pde1抑制劑的咪唑並吡嗪酮
IL248895A0 (en) Phosphatidylinositol 3-kinase inhibitors
IL248078B (en) Halogenated thf quinazoline amines as pde1 inhibitors
IL252866A0 (en) History of imidazopyridazine as pi3kbeta inhibitors
HK1232214A1 (zh) 作為 抑制劑的六氫呋喃並吡咯
IL249075B (en) agent for fluoroalkylation
HK1226296A1 (zh) 用於產生視黃酸的試劑
GB201418154D0 (en) Inhibitors
GB201407865D0 (en) Nucleases